Literature DB >> 17210688

Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression.

Mee Young Chang1, Janette Boulden, Erika Sutanto-Ward, James B Duhadaway, Alejandro Peralta Soler, Alexander J Muller, George C Prendergast.   

Abstract

Genes that modify oncogenesis may influence dormancy versus progression in cancer, thereby affecting clinical outcomes. The Bin1 gene encodes a nucleocytosolic adapter protein that interacts with and suppresses the cell transforming activity of Myc. Bin1 is often attenuated in breast cancer but its ability to negatively modify oncogenesis or progression in this context has not been gauged directly. In this study, we investigated the effects of mammary gland-specific deletion of Bin1 on initiation and progression of breast cancer in mice. Bin1 loss delayed the outgrowth and involution of the glandular ductal network during pregnancy but had no effect on tumor susceptibility. In contrast, in mice where tumors were initiated by the ras-activating carcinogen 7,12-dimethylbenz(a)anthracene, Bin1 loss strongly accentuated the formation of poorly differentiated tumors characterized by increased proliferation, survival, and motility. This effect was specific as Bin1 loss did not accentuate progression of tumors initiated by an overexpressed mouse mammary tumor virus-c-myc transgene, which on its own produced poorly differentiated and aggressive tumors. These findings suggest that Bin1 loss cooperates with ras activation to drive progression, establishing a role for Bin1 as a negative modifier of oncogenicity and progression in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210688     DOI: 10.1158/0008-5472.CAN-06-2742

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Authors:  Alexander J Muller; James B DuHadaway; Mee Young Chang; Arivudinambi Ramalingam; Erika Sutanto-Ward; Janette Boulden; Alejandro P Soler; Laura Mandik-Nayak; Susan K Gilmour; George C Prendergast
Journal:  Cancer Immunol Immunother       Date:  2010-07-17       Impact factor: 6.968

2.  Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma.

Authors:  Ke Pan; Xiao-ting Liang; Hua-kun Zhang; Jing-jing Zhao; Dan-dan Wang; Jian-jun Li; Qizhou Lian; Alfred E Chang; Qiao Li; Jian-chuan Xia
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

3.  Bin1 SRC homology 3 domain acts as a scaffold for myofiber sarcomere assembly.

Authors:  Pasan Fernando; Jacqueline S Sandoz; Wen Ding; Yves de Repentigny; Steve Brunette; John F Kelly; Rashmi Kothary; Lynn A Megeney
Journal:  J Biol Chem       Date:  2009-07-26       Impact factor: 5.157

Review 4.  Endocytic proteins in the regulation of nuclear signaling, transcription and tumorigenesis.

Authors:  Beata Pyrzynska; Iwona Pilecka; Marta Miaczynska
Journal:  Mol Oncol       Date:  2009-06-11       Impact factor: 6.603

5.  Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation.

Authors:  A Kumari; T Iwasaki; S Pyndiah; E K Cassimere; C D Palani; D Sakamuro
Journal:  Cell Death Differ       Date:  2014-09-26       Impact factor: 15.828

Review 6.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

7.  Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.

Authors:  Elizabeth S McKenna; Pablo Tamayo; Yoon-Jae Cho; Erik J Tillman; E Lorena Mora-Blanco; Courtney G Sansam; Edward C Koellhoffer; Scott L Pomeroy; Charles W M Roberts
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

8.  Isoproterenol Promotes Rapid Ryanodine Receptor Movement to Bridging Integrator 1 (BIN1)-Organized Dyads.

Authors:  Ying Fu; Seiji A Shaw; Robert Naami; Caresse L Vuong; Wassim A Basheer; Xiuqing Guo; TingTing Hong
Journal:  Circulation       Date:  2016-01-05       Impact factor: 29.690

Review 9.  Mammary cancer susceptibility: human genes and rodent models.

Authors:  Claude Szpirer; Josiane Szpirer
Journal:  Mamm Genome       Date:  2007-12-01       Impact factor: 2.957

Review 10.  BAR the door: cancer suppression by amphiphysin-like genes.

Authors:  George C Prendergast; Alexander J Muller; Arivudanambi Ramalingam; Mee Young Chang
Journal:  Biochim Biophys Acta       Date:  2008-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.